| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012272699 |
| P356 | DOI | 10.2165/00003495-200666100-00006 |
| P8608 | Fatcat ID | release_urqsefabu5ae3cd23cdfsffhcm |
| P698 | PubMed publication ID | 16903771 |
| P50 | author | Greg L Plosker | Q62563006 |
| David P Figgitt | Q62563786 | ||
| P2093 | author name string | Therese M Chapman | |
| P2860 | cites work | Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee | Q22242348 |
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
| Epidemiology of inflammatory bowel disease in Italy. | Q33781231 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Probiotics and inflammatory bowel disease: is there a scientific rationale? | Q33930749 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Use of probiotics in the treatment of inflammatory bowel disease | Q35051696 | ||
| Diagnosis and treatment of patients with pouchitis | Q35071346 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Guidelines for the management of inflammatory bowel disease in adults | Q35790559 | ||
| Probiotics and the management of inflammatory bowel disease. | Q35854517 | ||
| Probiotics and prebiotics in gastrointestinal disorders. | Q36036491 | ||
| Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression | Q38442953 | ||
| A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
| Functional modulation of enterocytes by gram-positive and gram-negative microorganisms | Q40580514 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. | Q40961532 | ||
| Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. | Q42674728 | ||
| Modulation of human dendritic cell phenotype and function by probiotic bacteria | Q43004747 | ||
| Effects of probiotic on intestinal mucosa of patients with ulcerative colitis | Q43159889 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. | Q43746137 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. | Q45126890 | ||
| Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition | Q45134589 | ||
| Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells | Q45304815 | ||
| Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Q46533800 | ||
| Beclomethasone dipropionate plus VSL#3 for the treatment of mild to moderate diverticular colitis: an open, pilot study | Q46586914 | ||
| DNA from probiotic bacteria modulates murine and human epithelial and immune function | Q47635337 | ||
| Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. | Q54511436 | ||
| Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells | Q57003105 | ||
| PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption | Q57004267 | ||
| Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea | Q57007134 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora | Q73092300 | ||
| Prevention is the best defense: probiotic prophylaxis of pouchitis | Q73351425 | ||
| Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements | Q73515877 | ||
| Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 | ||
| Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation | Q74637284 | ||
| Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? | Q77375025 | ||
| Ulcerative colitis | Q77601258 | ||
| Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis | Q80811554 | ||
| P433 | issue | 10 | |
| P921 | main subject | inflammation | Q101991 |
| inflammatory bowel diseases | Q917447 | ||
| probiotics | Q1816730 | ||
| P304 | page(s) | 1371-1387 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases | |
| P478 | volume | 66 |
| Q46495260 | Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease |
| Q37587217 | Balsalazide in treating colonic diseases |
| Q40643518 | Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials. |
| Q36687466 | Drug therapy of inflammatory bowel disease in fertile women |
| Q44023499 | Effects of a Lactobacillus reuteri BR11 mutant deficient in the cystine-transport system in a rat model of inflammatory bowel disease |
| Q37118873 | Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis |
| Q37434692 | Food allergy and autism spectrum disorders: is there a link? |
| Q42268439 | Host-probiotic interaction: new insight into the role of the endocannabinoid system by in vivo and ex vivo approaches |
| Q37182945 | Importance of nutrition in inflammatory bowel disease |
| Q38727911 | Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. |
| Q37907198 | Lessons from probiotic-host interaction studies in murine models of experimental colitis |
| Q36637753 | Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view |
| Q82665219 | OTC product: VSL #3: the living shield |
| Q54402802 | Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. |
| Q89967752 | Pathogenesis of Celiac Disease and Other Gluten Related Disorders in Wheat and Strategies for Mitigating Them |
| Q43937782 | Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. |
| Q33406281 | Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation |
| Q33572633 | Potential role of nutraceutical compounds in inflammatory bowel disease |
| Q37094595 | Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend? |
| Q38953644 | Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. |
| Q89576670 | Probiotics and Nigella sativa extract supplementation improved behavioral and electrophysiological effects of PTZ-induced chemical kindling in rats |
| Q24242115 | Probiotics for induction of remission in Crohn's disease |
| Q34364074 | Probiotics for the treatment of Clostridium difficile associated disease |
| Q27327276 | Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation |
| Q35278680 | Probiotics to counteract biofilm-associated infections: promising and conflicting data |
| Q36140994 | Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation |
| Q37345932 | Rationale for probiotic treatment strategies in inflammatory bowel disease |
| Q98892417 | Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease |
| Q28254207 | Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease |
| Q38174603 | The role of probiotics and prebiotics in inducing gut immunity. |
| Q59792682 | Therapeutic Microbiology: The Role of as Food Supplement for the Prevention/Treatment of Paediatric Diseases |
| Q37122235 | Therapeutic effects of four strains of probiotics on experimental colitis in mice |
| Q37615417 | Therapy of inflammatory bowel diseases in pregnancy and lactation |
| Q41430377 | Type 1 Diabetes: Urinary Proteomics and Protein Network Analysis Support Perturbation of Lysosomal Function |
| Q90300184 | Use of design of experiments to optimize the production of microbial probiotic biofilms |
| Q36140404 | VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial |
| Q38720190 | VSL#3 probiotic differently influences IEC-6 intestinal epithelial cell status and function. |
| Q44887797 | VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis |
Search more.